On November 11, 2024, Allogene Therapeutics, Inc. (the "Company") reported the company decided to discontinue enrollment in its Phase 1 cohort in the ALPHA2 clinical trial to evaluate cemacabtagene ansegedleucel ("cema-cel") as a treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) in patients previously treated with BTKi and BCL2i therapies (Press release, Allogene, NOV 11, 2024, View Source [SID1234648244]). While there is an ongoing need for additional treatment options for these patients, and interest in this cohort remains high among investigators, enrollment in the trial has been slower than anticipated due in part to the emergence of new alternative treatment options. Consequently, the Company is discontinuing enrollment in this trial and reallocating resources to other programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!